Ombretta Spinelli

Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C.

S. Lazzaroni, P. Lampertico, A. Gori, 2019, Journal of hepatology.

Real-life effectiveness and safety of Glecaprevir/Pibrentasvir among 723 Italian patients with chronic hepatitis C: The Navigator-II study

S. Lazzaroni, E. Buscarini, G. Spinzi, 2018 .

Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real‐Life Cohort Study

A. d’Arminio Monforte, E. Buscarini, P. Lampertico, 2021, Hepatology communications.

High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV‐infected patients treated in a real‐life setting

R. Bruno, M. Colaneri, P. Lampertico, 2020, Journal of viral hepatitis.

Comparison of three therapeutic regimens for genotype‐3 hepatitis C virus infection in a large real‐life multicentre cohort

A. d’Arminio Monforte, S. Lazzaroni, M. Valsecchi, 2020, Liver international : official journal of the International Association for the Study of the Liver.

Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study.

S. Lazzaroni, E. Buscarini, P. Lampertico, 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Real-life effectiveness and safety of Glecaprevir/Pibrentasvir among 723 Italian patients with chronic hepatitis C: The Navigator-II study

S. Lazzaroni, E. Buscarini, G. Spinzi, 2018 .